DelveInsight has launched a new report on “Acute Respiratory Distress Syndrome (ARDS) – Pipeline Insight 2020”.
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.
Request for Sample Page: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight
The launch of the emerging therapies is expected to significantly impact Postherpetic Neuralgia treatment scenario in the upcoming years:-
Drugs covered:
The key players in Postherpetic Neuralgia market are:
Acute Respiratory Distress Syndrome (ARDS) Analytical Perspective by DelveInsight
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
Report highlights
Key Questions
Table of Contents:
1. Report Introduction
2. Acute Respiratory Distress Syndrome (ARDS)
2.1. Overview
2.2. History
2.3. Acute Respiratory Distress Syndrome (ARDS) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Acute Respiratory Distress Syndrome (ARDS) Diagnosis
2.6.1. Diagnostic Guidelines
3. Acute Respiratory Distress Syndrome (ARDS) Current Treatment Patterns
3.1. Acute Respiratory Distress Syndrome (ARDS) Treatment Guidelines
4. Acute Respiratory Distress Syndrome (ARDS) – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Acute Respiratory Distress Syndrome (ARDS) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Acute Respiratory Distress Syndrome (ARDS) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Acute Respiratory Distress Syndrome (ARDS) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Acute Respiratory Distress Syndrome (ARDS) Late Stage Products (Phase-III)
7. Acute Respiratory Distress Syndrome (ARDS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Respiratory Distress Syndrome (ARDS) Discontinued Products
13. Acute Respiratory Distress Syndrome (ARDS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Acute Respiratory Distress Syndrome (ARDS) Key Companies
15. Acute Respiratory Distress Syndrome (ARDS) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Acute Respiratory Distress Syndrome (ARDS) Unmet Needs
18. Acute Respiratory Distress Syndrome (ARDS) Future Perspectives
19. Acute Respiratory Distress Syndrome (ARDS) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/